1-4 of 4
Hui Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4

Maciej T. Małecki, Rachel L. Batterham, Naveed Sattar, Joshua A. Levine, Ángel Rodríguez, Brandon K. Bergman, Hui Wang, Gabriela Ghimpeteanu, Clare J. Lee
Journal: Diabetes Care
Diabetes Care 2023;46(12):2292–2299
https://doi.org/10.2337/dc23-1135
Published: 12 October 2023
View articletitled, Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4
Open the PDF for Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4 in another window
Journal Articles

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge A. Jabbour, Juan P. Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2018;41(10):2136–2146
https://doi.org/10.2337/dc18-0680
Published: 06 August 2018
View articletitled, Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Open the PDF for Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Fasting Plasma Glucose at 24–28 Weeks to Screen for Gestational Diabetes Mellitus: New evidence from China

Wei-wei Zhu, MD, Ling Fan, MD, Hui-xia Yang, MD, Ling-ying Kong, MD, Shi-ping Su, MBBS, Zi-lian Wang, MD, Ya-Li Hu, MD, Mei-hua Zhang, MM, Li-Zhou Sun, MD, Yang Mi, MD, Xiu-ping Du, MM, Hua Zhang, MD, Yun-hui Wang, MM, Yin-ping Huang, MM, Li-ruo Zhong, MM, Hai-rong Wu, MM, Nan Li, MM, Yun-feng Wang, MM, Anil Kapur, MD
Journal: Diabetes Care
Diabetes Care 2013;36(7):2038–2040
https://doi.org/10.2337/dc12-2465
Published: 12 June 2013
View articletitled, Fasting Plasma Glucose at 24–28 Weeks to Screen for Gestational Diabetes Mellitus: New evidence from China
Open the PDF for Fasting Plasma Glucose at 24–28 Weeks to Screen for Gestational Diabetes Mellitus: New evidence from China in another window
Journal Articles

Evaluation of the Value of Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes Mellitus in China

Wei-wei Zhu, MD, Hui-xia Yang, MD, Yu-mei Wei, MD, Jie Yan, PHD, Zi-lian Wang, MD, Xue-lan Li, MM, Hai-rong Wu, MM, Nan Li, MM, Mei-hua Zhang, MM, Xing-hui Liu, MM, Hua Zhang, MD, Yun-hui Wang, MM, Jian-min Niu, MM, Yu-jie Gan, MM, Li-ruo Zhong, MM, Yun-feng Wang, MM, Anil Kapur, MD
Journal: Diabetes Care
Diabetes Care 2013;36(3):586–590
https://doi.org/10.2337/dc12-1157
Published: 13 February 2013
View articletitled, Evaluation of the Value of Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes Mellitus in China
Open the PDF for Evaluation of the Value of Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes Mellitus in China in another window